> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Reports 5.1% Cytokinetics Stake As Heart-Drug Label Decision Awaits FDA
- URL: https://www.bullished.co/state-street-reports-5-1-cytokinetics-stake-as-heart-drug-label-decision-awaits-fda-cc9e7274/
- Published: 2026-11-10T12:11:21.000Z
- Updated: 2026-11-10T12:11:21.000Z
- Description: The passive holding covers 7,143,229 shares; Cytokinetics awaits a decision on adding comparative trial results to Myqorzo's label.
- Author: Matteo Parrino
- Tags: SEC Filings, CYTK, Industry: Healthcare

State Street reported a [5.1% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000641/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Cytokinetics](https://www.bullished.co/tag/cytk/), which develops drugs targeting muscle function, in a passive ownership disclosure filed Tuesday. The holding covers 7,143,229 shares as of September 30, while the drugmaker awaits an FDA decision on adding trial evidence to its heart treatment's prescribing information.

## A Passive Stake, Shared Voting

State Street reported shared authority to [dispose of all](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000641/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) 7,143,229 shares. Its shared voting authority covers 6,775,887 shares, and it reported no sole voting authority.

The ownership percentage uses the disclosure's beneficial-ownership basis for Cytokinetics' common-stock class. State Street certified that the shares were bought and held through ordinary business activity, rather than for an effort to change or influence control of the company.

## Myqorzo's Next Label Decision

The FDA is set to decide this week whether to [add trial results](https://finance.yahoo.com/healthcare/articles/fda-decision-watch-summit-lung-102304677.html?ref=bullished.co) comparing Myqorzo with metoprolol to the treatment's prescribing information. The late-stage trial found greater improvement in exercise capacity with Myqorzo than with metoprolol.

Myqorzo, also called aficamten, is Cytokinetics' first commercial product: a tablet for adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition involving thickened heart muscle. The FDA and China's drug regulator approved it in December 2025; European Commission approval followed in February 2026.

Cytokinetics sells the treatment through its own U.S. sales force. It relies on licensing agreements with Sanofi for commercialization in China and Bayer in Japan. Approximately 10,000 U.S. cardiologists principally diagnose and treat hypertrophic cardiomyopathy.

## Aficamten Evidence Beyond Obstructive Disease

Cytokinetics' Monday announcement described [reduced heart-muscle thickness](https://www.globenewswire.com/news-release/2026/11/09/3398296/0/en/cytokinetics-announces-additional-data-related-to-aficamten-presented-at-the-hypertrophic-cardiomyopathy-medical-society-hcms-scientific-sessions-held-in-collaboration-with-the-ame.html?ref=bullished.co) compared with placebo after 36 weeks of aficamten treatment in patients with non-obstructive hypertrophic cardiomyopathy. Stephen Heitner, Cytokinetics' chief medical officer, said the findings pointed to potential reductions in structural markers of the disease.

The company's pipeline also includes omecamtiv mecarbil for heart failure, ulacamten and CK-089 for a type of muscular dystrophy. Cytokinetics had a market value of $7.7 billion as of Tuesday at 7:07 a.m. ET.

The pending FDA decision concerns adding the metoprolol-comparison evidence to an already-approved drug's prescribing information.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: CYTOKINETICS INC (CYTK)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000641/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week](https://finance.yahoo.com/healthcare/articles/fda-decision-watch-summit-lung-102304677.html?ref=bullished.co) — Yahoo Finance
- [Cytokinetics Announces Additional Data Related to Aficamten](https://www.globenewswire.com/news-release/2026/11/09/3398296/0/en/cytokinetics-announces-additional-data-related-to-aficamten-presented-at-the-hypertrophic-cardiomyopathy-medical-society-hcms-scientific-sessions-held-in-collaboration-with-the-ame.html?ref=bullished.co) — globenewswire.com

### More on Cytokinetics

- [Cytokinetics Says Heart Drug's New-Patient Share Is Nearing 45%, Targets Over 50% By Year-End](https://www.bullished.co/cytokinetics-says-heart-drugs-new-patient-share-is-nearing-45-targets-over-50-by-year-end-754e36c6/)

[All Cytokinetics (CYTK) coverage →](https://www.bullished.co/tag/cytk/)